Tyrosine kinase inhibitor, masitinib, limits neuronal damage, as measured by serum neurofilament light chain concentration in a model of neuroimmune-driven neurodegenerative disease.

酪氨酸激酶抑制剂马西替尼可限制神经损伤，这可以通过在神经免疫驱动的神经退行性疾病模型中血清神经丝轻链浓度来衡量